Lineage Therap(IL:LCTX)
ILA 325.70-1.20 (-0.37%)
IL:LCTX
Lineage Therap financials statements
ILA 325.70
At close:-1.20 (-0.37%)
Lineage Therap (LCTX) Ratios
3 Followers
Lineage Therap Ratios
IL:LCTX's free cash flow for Q2 2026 was $-7.19M. For the 2026 fiscal year, IL:LCTX's free cash flow was increased by $55.00K and operating cash flow was $-7.24M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.20 | 3.65 | 2.14 | 3.16 | 2.37 |
| Quick Ratio | 5.20 | 3.65 | 2.14 | 3.16 | 2.37 |
| Cash Ratio | 3.59 | 3.28 | 1.97 | 0.60 | 1.18 |
| Solvency Ratio | -0.91 | -0.50 | -0.53 | -0.49 | -0.50 |
| Operating Cash Flow Ratio | -1.66 | -1.65 | -1.59 | 0.06 | -0.50 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -10.08M | $ 14.79M | $ -555.00K | $ 8.27M | $ 27.90M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 |
| Debt-to-Equity Ratio | 0.05 | 0.03 | 0.05 | 0.05 | 0.03 |
| Debt-to-Capital Ratio | 0.05 | 0.03 | 0.04 | 0.05 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.53 | 1.44 | 1.59 | 1.69 | 1.89 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 |
| Net Debt to EBITDA | 0.56 | 2.41 | 1.35 | 0.34 | 1.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 94.19% | 96.48% | 92.50% | 95.05% | 63.40% |
| EBIT Margin | -471.61% | -195.62% | -276.50% | -153.17% | -1263.12% |
| EBITDA Margin | -466.80% | -189.21% | -268.76% | -148.22% | -1240.71% |
| Operating Profit Margin | -149.62% | -226.11% | -276.50% | -153.17% | -1263.12% |
| Pretax Profit Margin | -471.61% | -195.62% | -260.28% | -175.56% | -1110.63% |
| Net Profit Margin | -436.47% | -195.90% | -240.20% | -178.69% | -1104.18% |
| Continuous Operations Profit Margin | -436.47% | -195.62% | -240.12% | -179.24% | -1110.63% |
| Net Income Per EBT | 92.55% | 100.15% | 92.29% | 101.79% | 99.42% |
| EBT Per EBIT | 315.20% | 86.52% | 94.13% | 114.62% | 87.93% |
| Return on Assets (ROA) | -56.43% | -16.44% | -21.27% | -21.25% | -24.65% |
| Return on Equity (ROE) | -142.61% | -23.74% | -33.88% | -35.82% | -46.65% |
| Return on Capital Employed (ROCE) | -21.52% | -21.64% | -29.78% | -21.51% | -38.62% |
| Return on Invested Capital (ROIC) | -19.75% | -21.39% | -27.18% | -21.32% | -38.37% |
| Return on Tangible Assets | -90.49% | -33.23% | -49.07% | -39.63% | -36.75% |
| Earnings Yield | -16.53% | -18.50% | -11.42% | -13.23% | -10.67% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.32 | 14.89 | 12.01 | 49.51 | 0.08 |
| Payables Turnover | 0.36 | 0.28 | 0.33 | 0.30 | 0.40 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 3.10 | 2.16 | 1.88 | 2.59 | 0.80 |
| Asset Turnover | 0.13 | 0.08 | 0.09 | 0.12 | 0.02 |
| Working Capital Turnover Ratio | 0.34 | 0.33 | 0.29 | 0.28 | 0.08 |
| Cash Conversion Cycle | -972.03 | -1258.45 | -1084.73 | -1192.41 | 3856.12 |
| Days of Sales Outstanding | 39.17 | 24.52 | 30.40 | 7.37 | 4762.99 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1011.20 | 1282.96 | 1115.13 | 1199.79 | 906.87 |
| Operating Cycle | 39.17 | 24.52 | 30.40 | 7.37 | 4762.99 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.08 | -0.12 | -0.17 | 0.01 | -0.14 |
| Free Cash Flow Per Share | -0.08 | -0.12 | -0.17 | 0.00 | -0.15 |
| Dividend Paid and CapEx Coverage Ratio | -36.24 | -40.87 | -42.38 | 2.56 | -66.56 |
| Capital Expenditure Coverage Ratio | -36.24 | -40.87 | -42.38 | 2.56 | -66.56 |
| Operating Cash Flow Coverage Ratio | -7.82 | -9.19 | -9.68 | 0.27 | -8.41 |
| Operating Cash Flow to Sales Ratio | -1.30 | -2.43 | -3.19 | 0.07 | -6.05 |
| Free Cash Flow Yield | -5.06% | -23.52% | -15.54% | 0.33% | -5.93% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.96 | -5.40 | -8.76 | -7.56 | -9.37 |
| Price-to-Sales (P/S) Ratio | 26.40 | 10.59 | 21.04 | 13.51 | 103.45 |
| Price-to-Book (P/B) Ratio | 8.63 | 1.28 | 2.97 | 2.71 | 4.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -19.77 | -4.25 | -6.44 | 307.52 | -16.85 |
| Price-to-Operating Cash Flow Ratio | -20.31 | -4.36 | -6.59 | 187.59 | -17.11 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | 0.24 | 0.44 | 0.18 | -0.11 |
| Enterprise Value Multiple | -5.09 | -3.19 | -6.48 | -8.77 | -7.24 |
| Enterprise Value | 345.92M | 57.32M | 155.71M | 191.20M | 350.09M |
| EV to EBITDA | -5.09 | -3.19 | -6.48 | -8.77 | -7.24 |
| EV to Sales | 23.76 | 6.03 | 17.41 | 13.00 | 89.86 |
| EV to Free Cash Flow | -17.79 | -2.42 | -5.33 | 295.97 | -14.64 |
| EV to Operating Cash Flow | -18.28 | -2.48 | -5.45 | 180.55 | -14.86 |
| Tangible Book Value Per Share | 0.00 | 0.10 | 0.03 | 0.09 | 0.20 |
| Shareholders’ Equity Per Share | 0.19 | 0.39 | 0.37 | 0.43 | 0.56 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.07 | 0.00 | 0.08 | -0.02 | 0.00 |
| Revenue Per Share | 0.06 | 0.05 | 0.05 | 0.09 | 0.02 |
| Net Income Per Share | -0.28 | -0.09 | -0.12 | -0.15 | -0.26 |
| Tax Burden | 0.93 | 1.00 | 0.92 | 1.02 | 0.99 |
| Interest Burden | 1.00 | 1.00 | 0.94 | 1.15 | 0.88 |
| Research & Development to Revenue | 1.22 | 1.31 | 1.76 | 0.95 | 8.70 |
| SG&A to Revenue | 1.27 | 1.91 | 1.93 | 1.53 | 4.67 |
| Stock-Based Compensation to Revenue | 0.33 | 0.53 | 0.52 | 0.29 | 0.90 |
| Income Quality | 0.30 | 1.24 | 1.33 | -0.04 | 0.54 |
Currency in USD
